Recent

% | $
Quotes you view appear here for quick access.

Aeterna Zentaris Inc. Message Board

  • skitahoe skitahoe Jan 31, 2013 9:46 PM Flag

    Compare CLSN with AEZS

    Both have had their market caps diminished by 80% or more on a trial failure, but I believe that's where the comparison ends. CLSN has no other pipeline products, they have Thermodox in Phase II Trials in other cancers, but no Phase III's. In short, AEZS has far more potential with a strong pipeline, one approved product, one product soon to submit an NDA, one product about to start Phase III, and finally Perifosine, the failed product in Colon Cancer about to report on what they're told in a peek at the data in a second Phase III Trial in MM.

    I believe anyone seriously comparing the two will recognize AEZS ought to be worth far more.

    Gary

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AEZS
0.54+0.012(+2.27%)May 6 4:00 PMEDT